Invesaro

Stocks Health care ACH

NYSE · Health care

Accendra Health Inc (ACH)

Accendra Health Inc brought in $2.6B of revenue over the twelve months to June 30, 2026, up 247.0% from a year earlier. It posted a net loss of $302.1M. In fiscal 2025 capital spending exceeded operating cash flow by $292.7M. At June 30, 2026 it held $7.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.

Revenue (last 12 months)
$2.6B
+247.0% year on year
Net margin
-11.4%

What Accendra Health Inc does

Accendra Health Inc is registered with the SEC under industry code SIC 5047 (Wholesale-Medical, Dental & Hospital Equipment & Supplies). Its shares trade on NYSE under the ticker ACH.

Revenue and profit by year

Revenue
FY18: $9.4B $9.4B FY18FY19: $9.2B $9.2B FY19FY20: $8.5B $8.5B FY20FY21: $9.8B $9.8B FY21FY22: $10B $10B FY22FY23: $2.6B $2.6B FY23FY24: $2.7B $2.7B FY24FY25: $2.8B $2.8B FY25
Net income
FY18: -$437M -$437M FY18FY19: -$62.4M -$62.4M FY19FY20: $29.9M $29.9M FY20FY21: $221.6M $221.6M FY21FY22: $22.4M $22.4M FY22FY23: -$41.3M -$41.3M FY23FY24: -$362.7M -$362.7M FY24FY25: -$1.1B -$1.1B FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$2.8B$27.5M-$1.1B-$14.31-$292.7M
2024$2.7B-$217.7M-$362.7M-$4.73-$8.8M
2023$2.6B$133.2M-$41.3M-$0.53$568.3M
2022$10B$142.9M$22.4M$0.29$166.9M
2021$9.8B$368.5M$221.6M$2.94$83.2M
2020$8.5B$204.1M$29.9M$0.47$288.8M

Latest SEC filings

What Accendra Health Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 17, 2026
    Executive or director change 8-K
  2. August 17, 2026
    Investor disclosure 8-K
  3. August 10, 2026
    Material agreement 8-K
  4. August 10, 2026
    Quarterly report 10-Q · period to June 30, 2026
  5. August 10, 2026
    Quarterly results 8-K
  6. August 10, 2026
    Executive or director change 8-K
  7. July 15, 2026
    Shelf registration to sell securities S-3
  8. June 25, 2026
    Other event 8-K
  9. June 15, 2026
    Material agreement 8-K
  10. May 29, 2026
    Conflict minerals disclosure SD

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 24, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about ACH

What does Accendra Health Inc do?

Accendra Health Inc is registered with the SEC under industry code SIC 5047 (Wholesale-Medical, Dental & Hospital Equipment & Supplies). Its shares trade on NYSE under the ticker ACH.

Is Accendra Health Inc profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $302.1M on revenue of $2.6B.

How much revenue does Accendra Health Inc make?

Over the twelve months to June 30, 2026 Accendra Health Inc reported revenue of $2.6B. That is 247.0% more than a year earlier.

When did Accendra Health Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 24, 2026.

Similar companies

HSIC
Henry Schein Inc
UNH
Unitedhealth Group Inc
MCK
McKesson Corp
COR
Cencora, Inc.
CI
Cigna Group
CAH
Cardinal Health Inc

Follow ACH

Get an email when Accendra Health Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow ACH: get an email when it files

Where the numbers come from

Financial figures are the values Accendra Health Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.